 |
| 09-Feb-10 | Upgrade |
Roth Capital |
Hold → Buy |
$23 |
|
| 08-Feb-10 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 04-Feb-10 | Reiterated |
Roth Capital |
Hold |
$17 → $23 |
|
| 08-Jan-10 | Downgrade |
Morgan Joseph |
Buy → Hold |
|
|
| 09-Dec-09 | Upgrade |
Collins Stewart |
Hold → Buy |
$22 |
|
| 29-Oct-09 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
| 19-Oct-09 | Downgrade |
Roth Capital |
Buy → Hold |
$17 |
|
| 08-Oct-09 | Reiterated |
Jefferies & Co |
Buy |
$18 → $20 |
|
| 31-Jul-09 | Upgrade |
Wedbush Morgan |
Underperform → Neutral |
$16 → $20 |
|
| 31-Jul-09 | Reiterated |
Jefferies & Co |
Buy |
$16 → $18 |
|
| 27-Jul-09 | Reiterated |
Roth Capital |
Buy |
$18 → $17 |
|
| 20-May-09 | Reiterated |
Roth Capital |
Buy |
$14 → $18 |
|
| 21-Apr-09 | Initiated |
Morgan Joseph |
Buy |
$20 |
|
| 31-Mar-09 | Initiated |
Thomas Weisel |
Market Weight |
$14 |
|
| 27-Mar-09 | Initiated |
Piper Jaffray |
Neutral |
|
|
| 12-Mar-09 | Reiterated |
Leerink Swann |
Outperform |
$22 → $21 |
|
| 12-Mar-09 | Initiated |
FTN Equity Capital |
Buy |
|
|
| 04-Mar-09 | Upgrade |
Citigroup |
Hold → Buy |
$17 |
|
| 24-Feb-09 | Upgrade |
Roth Capital |
Hold → Buy |
|
|
| 23-Feb-09 | Reiterated |
Jefferies & Co |
Buy |
$25 → $16 |
|
|
|
| 09-Feb-10 01:31PM | Biotech Stocks: Cell Therapeutics, AstraZeneca lead drug stocks at MarketWatch |
| 11:13AM | BioMarin to Expand, Offers Guidance Zacks.com |
| 10:23AM | Biotech Stocks: Drug stocks gain; Cell Therapeutics rebounds at MarketWatch |
| 09:33AM | Caterpillar: Analysts' Upgrades, Downgrades at TheStreet.com |
| 02:03AM | Biomarin Pharm upgraded by Roth Capital Briefing.com |
| 08-Feb-10 04:31PM | CVS Caremark, Motorola, Hasbro are big movers AP |
| 01:14PM | Biotech Stocks: Drug stocks turn higher; Cell Therapeutics tumbles at MarketWatch |
| 11:06AM | BioMarin shares fall, Brean analyst downgrades AP |
| 10:52AM | Biotech Stocks: BioMarin, Cell Therapeutics lead drug stocks south at MarketWatch |
| 10:36AM | China Biotech Week in Review: New Investments in Life Science at Seeking Alpha |
| 05-Feb-10 05:20PM | BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 08:46AM | BioMarin to buy LEAD for $97M, gives 2010 outlook AP |
| 04-Feb-10 06:05PM | BioMarin to buy Lead Therapeutics for $18M at bizjournals.com |
| 04:23PM | Stocks Outlook: Small Caps Still Have Way to Go Higher at CNBC |
| 04:06PM | BioMarin Announces 2010 Guidance PR Newswire |
| 04:03PM | BioMarin to Acquire LEAD Therapeutics PR Newswire |
| 04:00PM | InPlay: BioMarin Reports "Encouraging" Preliminary Data on BMN 110 for MPS IVA; co to host conf call at 5 p.m. ET Briefing.com |
| 04:00PM | BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA PR Newswire |
| 03:54PM | Investing Tips: Small Caps Still Have Way to Go Higher at CNBC |
| 02-Feb-10 09:00AM | BioMarin to Present at the BIO CEO and Investor Conference PR Newswire |
| 09:00AM | BioMarin to Host Fourth Quarter and Full Year 2009 Financial Results Conference Call and Webcast on Tuesday, February 23 at 5:00 p.m. ET PR Newswire |
| 27-Jan-10 09:48AM | 67% Decline In Consumable Cost For Human Genome Sequencing Seen In 2010 By First Analysis Equity Valuation Expert Wall Street Transcript |
| 21-Jan-10 03:28PM | The Noble Gesture That Wasn't at Motley Fool |
| 20-Jan-10 03:33PM | Study: orphan drug applications doubled in 200s AP |
| 11-Jan-10 09:00AM | BioMarin Initiates Phase 1 Clinical Study of BMN 195 for Duchenne Muscular Dystrophy PR Newswire |
| 07-Jan-10 09:30AM | Wall to Wall Street Coverage: Upgrades and Downgrades Minyanville +5.63% |
| 06-Jan-10 08:40AM | BioMarin Drug Cleared in Europe Zacks.com |
| 05-Jan-10 04:00PM | Amifampridine Phosphate Receives Marketing Approval in the EU for LEMS PR Newswire |
| 09:00AM | BioMarin to Present at the J.P. Morgan Healthcare Conference PR Newswire |
| 09-Dec-09 11:07AM | CFO Interview - BioPharm Asia, Inc., Michael Guo Wall Street Transcript |
| 09:34AM | Premarket roundup: Men's Wearhouse, Cisco AP |
| 09:27AM | Ahead of the Bell: BioMarin Pharma upgraded AP |
| 02-Dec-09 11:16AM | Orphan Drug Status for BioMarin Drug Zacks.com |
| 01-Dec-09 03:13PM | Pfizer Takes In an Orphan on the Cheap at Motley Fool |
| 30-Nov-09 02:10PM | BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance at Seeking Alpha |
| 09:58AM | UPDATE - BioMarin autoimmune disease drug gets orphan status at Reuters |
| 09:27AM | BioMarin treatment gets special FDA status AP |
| 09:00AM | FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS PR Newswire |
| 28-Nov-09 10:23AM | Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector Wall Street Transcript |
| 27-Nov-09 11:24AM | The Next Million-Dollar Penny Stock at Motley Fool |
| 24-Nov-09 04:00PM | BioMarin to Present at the NASDAQ OMX 23rd Investor Program PR Newswire |
| 13-Nov-09 11:58AM | Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme PR Newswire |
| 09-Nov-09 01:53PM | Healthcare Bill Will Be Law By New Year Says Morningstar Strategist Wall Street Transcript |
| 05-Nov-09 04:00PM | United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food PR Newswire |
| 04-Nov-09 09:00AM | BioMarin to Present at the Credit Suisse Healthcare Conference PR Newswire |
| 03-Nov-09 09:04AM | BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials |
| 02-Nov-09 01:59PM | Finally Convinced? Benlysta Works! at Motley Fool |
| 30-Oct-09 03:37PM | Earnings? Yawn. Trial Data? Moving! at Motley Fool |
| 11:57AM | This Week's 5 Smartest Stock Moves at Motley Fool |
| 29-Oct-09 04:00PM | BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 03:25PM | Small and Volatile, but Not for Long at Motley Fool |
| 12:41PM | Biotech Stocks: BioMarin, Human Genome lead drug stocks higher at MarketWatch |
| 28-Oct-09 05:52PM | BioMarin 3Q profit jumps improved drug sales AP -6.61% |
| 05:00PM | BioMarin Pharmaceutical Inc. Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:41PM | BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 04:00PM | BioMarin Announces Third Quarter 2009 Financial Results PR Newswire |
| 07:07AM | Q3 2009 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN |
| 27-Oct-09 04:00PM | BioMarin to Present at the Oppenheimer Healthcare Conference PR Newswire |
| 03:32PM | Small Market, Small Acquisition, Still a Good Move at Motley Fool |
| 12:12PM | BioMarin Purchases Huxley Zacks.com |
| 10:56AM | The Bull and Bear Story on GTx's Pending Drug Decision: BioBuzz at TheStreet.com |
| 10:56AM | The Bull and Bear Story on GTx's Pending Drug Approval: BioBuzz at TheStreet.com |
| 07:37AM | Big-Cap Biotech Worries Lead Sector Down: BioBuzz at TheStreet.com |
| 26-Oct-09 07:05PM | BioMarin to buy Huxley Pharmaceuticals at bizjournals.com |
| 05:06PM | BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 04:40PM | BioMarin Acquires Huxley Pharmaceuticals, Inc. PR Newswire |
| 21-Oct-09 04:01PM | Build Your Fortune With These Winners at Motley Fool |
| 20-Oct-09 10:14AM | Biotech Mergers And Acquisitions Will Accelerate According To Wedbush Morgan Expert Analyst As More Expensive Phase III Trials Force Small Biotech Companies Into Large Pharma Distribution And Finance Organizations Wall Street Transcript |
| 08:04AM | Immunostimulatory Antibodies Seen As Potential Treatment For Broad Range Of Cancers And Catalyst For Investment Returns By Ladenburg Thalmann Analyst Wall Street Transcript |
| 19-Oct-09 02:00PM | Biotech Stocks: Amgen, BioMarin slide; Human Genome gains at MarketWatch |
| 10:20AM | Biotech Stocks: Drug stocks split; Amgen falls on FDA delay at MarketWatch |
| 14-Oct-09 11:32PM | UPDATE - La Jolla to seek stockholders' approval of dissolution at Reuters |
| 09-Oct-09 03:20PM | The Next Million-Dollar Penny Stock at Motley Fool |
| 09:00AM | BioMarin's Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times PR Newswire |
| 01-Oct-09 02:51PM | [$$] Biotechs That Could Rebound at Barrons.com |
| 30-Sep-09 04:00PM | United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food PR Newswire |
| 09:00AM | BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET PR Newswire |
| 23-Sep-09 12:31PM | BioMarin Begins Mid-Stage Trial Zacks.com |
| 22-Sep-09 04:00PM | BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU PR Newswire |
| 21-Sep-09 03:09AM | Cramer's Lightning Round - Back in the Boom Room (9/18/09) at Seeking Alpha |
| 17-Sep-09 12:22PM | Citi analyst reaffirms BioMarin as a 'buy' AP |
| 07:15AM | Psst... These Drug Firms Are Getting Bought: BioBuzz at TheStreet.com |
| 16-Sep-09 08:35PM | Lightning Round: Microsoft, Viacom, Banco Santander and More at CNBC |
| 15-Sep-09 09:00AM | BioMarin to Present at the UBS Global Life Sciences Conference PR Newswire |
| 11-Sep-09 03:50PM | Buzz of the Street: In and Out of First Solar at Minyanville.com |
| 10-Sep-09 04:09PM | Thursday's Options Recap at Seeking Alpha +5.54% |
| 01:12PM | Halftime Report: Trading Market's 5-Day Advance at CNBC |
| 08-Sep-09 12:37PM | Sector Snap: Analyst keeps positive biotech view AP |
| 09:00AM | BioMarin to Present at the Morgan Stanley Healthcare Conference PR Newswire |
| 02-Sep-09 09:00AM | BioMarin to Present at the Thomas Weisel Partners Healthcare Conference PR Newswire |
| 09:00AM | BioMarin to Present at the Baird Healthcare Conference PR Newswire |
| 28-Aug-09 04:01PM | Is There Life After a 714% Return? at Motley Fool |
| 11:20AM | 7 Stocks With a Bright Future at Motley Fool |
| 19-Aug-09 09:00AM | Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting PR Newswire |
| 18-Aug-09 12:01AM | [$$] Biotechs to Buck the Market Correction at Barron's Online |
| 05-Aug-09 03:36PM | The Cash Cow Is Out of Milk at Motley Fool |
| 01:00AM | Ratings Changes: Cablevision, Eaton Vance at TheStreet.com |
| 01-Aug-09 09:20AM | New Star Analyst Rankings for BioMarin Pharmaceutical Inc. StarMine |
| 31-Jul-09 04:28PM | BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online +10.80% |
| 03:01PM | The Little Orphan That Could at Motley Fool |
|
|
| BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase. Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation. The company was founded in 1996 and is headquartered in Novato, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Wood Mark | VP, Human Resources | Feb 03 | Option Exercise | 11.74 | 377 | 4,426 | 8,458 | Feb 05 05:02 PM | | Wood Mark | VP, Human Resources | Feb 03 | Sale | 21.00 | 377 | 7,917 | 8,081 | Feb 05 05:02 PM | | Wood Mark | VP, Human Resources | Jan 21 | Option Exercise | 11.74 | 144 | 1,691 | 8,225 | Jan 25 01:29 PM | | Wood Mark | VP, Human Resources | Jan 21 | Sale | 21.05 | 144 | 3,031 | 8,081 | Jan 25 01:29 PM | | Wood Mark | VP, Human Resources | Jan 19 | Option Exercise | 13.36 | 17,499 | 233,786 | 25,580 | Jan 21 08:01 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 19 | Sale | 20.89 | 3,500 | 73,115 | 50,440 | Jan 21 08:07 PM | | Wood Mark | VP, Human Resources | Jan 19 | Sale | 21.00 | 17,499 | 367,479 | 8,081 | Jan 21 08:01 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 22 | Sale | 18.83 | 1,500 | 28,245 | 53,940 | Dec 24 02:05 PM | | Davis George Eric | VP, General Counsel | Dec 02 | Option Exercise | 7.32 | 21,000 | 153,720 | 41,453 | Dec 04 01:57 PM | | Davis George Eric | VP, General Counsel | Dec 02 | Sale | 17.25 | 21,000 | 362,250 | 20,453 | Dec 04 01:57 PM | | Wood Mark | VP, Human Resources | Aug 28 | Option Exercise | 6.13 | 177 | 1,085 | 8,258 | Sep 01 01:19 PM | | Wood Mark | VP, Human Resources | Aug 28 | Sale | 16.50 | 177 | 2,921 | 8,081 | Sep 01 01:19 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Aug 10 | Sale | 15.94 | 2,000 | 31,889 | 55,440 | Aug 11 06:39 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Aug 07 | Sale | 15.95 | 2,000 | 31,902 | 57,440 | Aug 11 06:39 PM | | Wood Mark | VP, Human Resources | Jul 08 | Sale | 13.89 | 456 | 6,333 | 8,081 | Jul 08 07:39 PM | | Wood Mark | VP, Human Resources | Jul 07 | Option Exercise | 0.00 | 1,250 | 0 | 8,537 | Jul 08 07:39 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jun 22 | Option Exercise | 0.00 | 7,500 | 0 | 59,440 | Jun 24 04:16 PM | | BAFFI ROBERT | SVP, Technical Operations | Jun 22 | Option Exercise | 0.00 | 2,000 | 0 | 53,187 | Jun 24 04:14 PM | | ASELAGE STEVE | SVP, Chief Business Officer | Jun 22 | Option Exercise | 0.00 | 2,500 | 0 | 50,916 | Jun 24 04:13 PM | | Cooper Jeffrey H | SVP, Chief Financial Officer | Jun 22 | Option Exercise | 0.00 | 2,000 | 0 | 18,502 | Jun 24 03:18 PM | | Davis George Eric | VP, General Counsel | Jun 22 | Option Exercise | 0.00 | 1,750 | 0 | 20,453 | Jun 24 03:16 PM | | Wood Mark | VP, Human Resources | Jun 22 | Option Exercise | 0.00 | 1,000 | 0 | 7,650 | Jun 24 03:15 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jun 12 | Buy | 14.52 | 1,500 | 21,780 | 51,940 | Jun 16 03:30 PM | | Davis George Eric | VP, General Counsel | Jun 11 | Sale | 14.47 | 2,500 | 36,175 | 16,203 | Jun 15 07:26 PM | | MEIER RICHARD A | Director | Jun 05 | Buy | 13.70 | 2,000 | 27,400 | 10,250 | Jun 09 05:57 PM | | MEIER RICHARD A | Director | Mar 13 | Buy | 11.45 | 1,000 | 11,450 | 4,250 | Mar 17 05:14 PM | | KLEIN JOSEPH III | Director | Mar 05 | Buy | 10.07 | 5,000 | 50,363 | 42,500 | Mar 13 08:11 PM | | MEIER RICHARD A | Director | Mar 03 | Buy | 10.75 | 1,000 | 10,750 | 3,250 | Mar 04 07:27 PM | | KLEIN JOSEPH III | Director | Mar 03 | Buy | 10.56 | 5,000 | 52,818 | 37,500 | Mar 04 07:22 PM | | KAKKIS EMIL D | Chief Medical Officer | Mar 02 | Option Exercise | 6.43 | 7,897 | 50,778 | 47,518 | Mar 04 07:29 PM | | MEIER RICHARD A | Director | Mar 02 | Buy | 11.10 | 1,000 | 11,100 | 2,250 | Mar 04 07:27 PM | | KAKKIS EMIL D | Chief Medical Officer | Mar 02 | Sale | 11.70 | 7,897 | 92,396 | 39,621 | Mar 04 07:29 PM | | KLEIN JOSEPH III | Director | Feb 24 | Buy | 12.08 | 10,000 | 120,784 | 32,500 | Feb 26 03:34 PM | | KAKKIS EMIL D | Chief Medical Officer | Feb 03 | Option Exercise | 6.43 | 17,000 | 109,310 | 56,621 | Feb 05 07:34 PM | | KAKKIS EMIL D | Chief Medical Officer | Feb 03 | Sale | 19.14 | 17,000 | 325,373 | 39,621 | Feb 05 07:34 PM | | Wood Mark | VP, Human Resources | Jan 22 | Option Exercise | 6.13 | 1 | 6 | 651 | Jan 23 02:15 PM | | Wood Mark | VP, Human Resources | Jan 22 | Sale | 19.05 | 1 | 19 | 650 | Jan 23 02:15 PM | | Wood Mark | VP, Human Resources | Jan 21 | Option Exercise | 6.13 | 177 | 1,085 | 827 | Jan 23 02:15 PM | | Wood Mark | VP, Human Resources | Jan 21 | Sale | 19.30 | 177 | 3,415 | 650 | Jan 23 02:15 PM | | Wood Mark | VP, Human Resources | Jan 16 | Option Exercise | 12.59 | 2,501 | 31,482 | 3,151 | Jan 21 11:32 AM | | Wood Mark | VP, Human Resources | Jan 16 | Sale | 21.00 | 2,501 | 52,521 | 650 | Jan 21 11:32 AM | | KAKKIS EMIL D | Chief Medical officer | Jan 02 | Option Exercise | 6.31 | 17,000 | 107,335 | 56,621 | Jan 06 06:49 PM | | KAKKIS EMIL D | Chief Medical officer | Jan 02 | Sale | 17.57 | 17,000 | 298,690 | 39,621 | Jan 06 06:49 PM |
|
|
|
|
|
|
